Literature DB >> 18825681

Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma.

Mauricio Silva1, Angel Moya, Marina Berenguer, Fernando Sanjuan, Rafael López-Andujar, Eugenia Pareja, Rodrigo Torres-Quevedo, Victoria Aguilera, Eva Montalva, Manuel De Juan, Angelo Mattos, Martín Prieto, José Mir.   

Abstract

Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community. The main aim of this study was to evaluate the survival rates and recurrence probabilities of a new proposal for criteria (up to 3 tumors, each no larger than 5 cm, and a cumulative tumor burden </= 10 cm). Patients with cirrhosis and HCC included on the waiting list (WL) from 1991 to 2006 were retrospectively analyzed. Outcomes in patients who had tumors within and beyond the MC were compared. The survival analysis was done (1) with the intention-to-treat principle and (2) among transplanted patients. A total of 281 patients were included in WL. Twenty-four cases did not undergo OLT (a dropout rate of 8.5%); all but 1 case had tumors within the MC. Of the 257 transplanted patients, 26 had tumors beyond the MC in the pre-OLT evaluation. Based on the intention-to-treat analysis, the 5-year survival was 56% versus 66% in patients who had tumors within and beyond the MC, respectively (P = 0.487). Among transplanted patients, the 5-year survival was 62% versus 69%, respectively (P = 0.734). Through multivariate analysis, microvascular invasion was an independent prognostic factor of poor survival (P = 0.004). The recurrence probabilities at 1 and 5 years were 7% versus 12% and 14% versus 28% in patients with tumors within and beyond the MC, respectively (P = 0.063). The multivariate analysis demonstrated that both poorly differentiated tumors (P < 0.001) and microvascular invasion (P < 0.001) increased the risk of recurrence. The expansion to up to 3 nodules, each up to 5 cm, and a cumulative tumor burden </= 10 cm did not result in a reduction of survival in comparison with patients who had tumors within the MC. (c) 2008 AASLD.

Entities:  

Mesh:

Year:  2008        PMID: 18825681     DOI: 10.1002/lt.21576

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  32 in total

1.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

2.  Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma.

Authors:  Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

3.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 4.  Surgical approach for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Junichi Shindoh; Masaji Hashimoto; Goro Watanabe
Journal:  World J Hepatol       Date:  2015-01-27

5.  Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.

Authors:  Mohammed Elshamy; Federico Aucejo; K V Narayanan Menon; Bijan Eghtesad
Journal:  World J Hepatol       Date:  2016-07-28

6.  Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage.

Authors:  Kuniya Tanaka
Journal:  Hepatobiliary Surg Nutr       Date:  2017-08       Impact factor: 7.293

Review 7.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

Review 8.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

9.  Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.

Authors:  Guang-Qin Xiao; Chang Liu; Da-Li Liu; Jia-Yin Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 10.  New advances in hepatocellular carcinoma.

Authors:  Sonia Pascual; Iván Herrera; Javier Irurzun
Journal:  World J Hepatol       Date:  2016-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.